A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder

Journal of Clinical Psychiatry

Volumn 76, Issue 5, 2015, Pages 575-582

  Jacobsen, Paula L ^a   Mahableshwarkar, Atul R ^a   Serenko, Michael ^a   Chan, Serena ^a   Trivedi, Madhukar H ^b  

^a TAKEDA DEVELOPMENT CENTER AMERICAS   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VORTIOXETINE; PIPERAZINE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; SULFIDE;

ADULT; AGED; ARTICLE; BLOOD CHEMISTRY; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DSM-IV-TR; FATIGUE; FEMALE; HAMILTON ANXIETY SCALE; HEADACHE; HEMATOLOGY; HUMAN; INSOMNIA; KIDNEY INFECTION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; NAUSEA; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; SHEEHAN DISABILITY SCALE; SUICIDAL IDEATION; SUICIDE ATTEMPT; UNSPECIFIED SIDE EFFECT; VIRAL UPPER RESPIRATORY TRACT INFECTION; VITAL SIGN; VOMITING; WEIGHT CHANGE; XEROSTOMIA; DEPRESSIVE DISORDER, MAJOR; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PLACEBOS; SEROTONIN UPTAKE INHIBITORS; SULFIDES; TREATMENT OUTCOME;

EID: 84932119867     PISSN: 01606689     EISSN: 15552101     Source Type: Journal    
DOI: 10.4088/JCP.14m09335     Document Type: Article

References (34)

1. Ustün TB, Ayuso-Mateos JL, Chatterji S, et al. Global burden of depressive disorders in the year 2000. Br J Psychiatry. 2004;184(5):386-392.
2. Angst J, Angst F, Stassen HH. Suicide risk in patients with major depressive disorder. J Clin Psychiatry. 1999;60(suppl 2):57-62, discussion 75-76, 113-116.
3. Kessler RC, Borges G, Walters EE. Prevalence of and risk factors for lifetime suicide attempts in the National Comorbidity Survey. Arch Gen Psychiatry. 1999;56(7):617-626.
4. Trivedi MH. Major depressive disorder: remission of associated symptoms. J Clin Psychiatry. 2006;67(suppl 6):27-32.
5. Trivedi MH, Rush AJ, Wisniewski SR, et al; STAR∗D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR&z.ast;D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40.
6. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR&z.ast;D report. Am J Psychiatry. 2006;163(11):1905-1917.
7. Oestergaard S, Møldrup C. Optimal duration of combined psychotherapy and pharmacotherapy for patients with moderate and severe depression: a meta-analysis. J Affect Disord. 2011;131(1-3):24-36.
8. Ginsberg LD. Impact of drug tolerability on the selection of antidepressant treatment in patients with major depressive disorder. CNS Spectr. 2009;14(suppl 12):8-14.
9. Ashton AK, Jamerson BD, Weinstein WL, et al. Antidepressant-related adverse effects impacting treatment compliance: Results of a patient survey. Curr Ther Res Clin Exp. 2005;66(2):96-106.
10. Morehouse R, Macqueen G, Kennedy SH. Barriers to achieving treatment goals: a focus on sleep disturbance and sexual dysfunction. J Affect Disord. 2011;132(suppl 1):S14-S20.
11. Bang-Andersen B, Ruhland T, Jørgensen M, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011;54(9):3206-3221.
12. Westrich L, Pehrson A, Zhong H, et al. In vitro and in vivo effects for the multimodal antidepressant vortioxetine (Lu AA21004) at human and rat targets. Int J Psychiatry Clin Pract. 2012;16(suppl 1):47.
13. Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther. 2015;145C:43-57.
14. Alvarez E, Perez V, Dragheim M, et al. A double-blind, randomized, placebocontrolled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol. 2012;15(5):589-600.
15. Henigsberg N, Mahableshwarkar AR, Jacobsen P, et al. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry. 2012;73(7):953-959.
16. Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebocontrolled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012;27(4):215-223.
17. Boulenger JP, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebocontrolled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol. 2014;29(3):138-149.
18. Mahableshwarkar AR, Jacobsen PL, Chen Y, et al. NR3-055: a randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Poster presented at the 166th American Psychiatric Association (APA) Annual Meeting; May 18-22, 2013; San Francisco, CA.
19. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389.
20. American Psychiatric Association. Major depressive episode - diagnostic criteria. Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Associaion; 2000:327.
21. Guy W. Clinical Global Impressions (028-CGI): ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration; 1976:218-222.
22. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-55.
23. Sheehan DV. The Sheehan Disability Scales. The Anxiety Disease and How to Overcome It. New York, NY: Charles Scribner & Sons; 1983:151.
24. Posner K, Brent D, Lucas C, et al. Columbia-Suicide Severity Rating Scale (C-SSRS). New York, NY: Columbia University Medical Center; 2008.
25. McGahuey CA, Gelenberg AJ, Laukes CA, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther. 2000;26(1):25-40.
26. Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998;44(2):77-87.
27. Naik H, Chan S, Vakilynejad M, et al. P02: a population pharmacokinetic (PK)-pharmacodynamic (PD) meta analysis of vortioxetine (Lu AA21004) in patient with major depressive disorder (MDD). Poster presented at the 166th American Psychiatric Association (APA) Annual Meeting; May 18-22, 2013; San Francisco, CA.
28. Jain R, Mahableshwarkar AR, Jacobsen PL, et al. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol. 2013;16(2):313-321.
29. Baldwin DS, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol. 2012;22(7):482-491.
30. Mahableshwarkar AR, Jacobsen PL, Chen Y. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin. 2013;29(3):217-226.
31. Haddad P. Newer antidepressants and the discontinuation syndrome. J Clin Psychiatry. 1997;58(suppl 7):17-21, discussion 22.
32. Schatzberg AF, Haddad P, Kaplan EM, et al. Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Discontinuation Consensus panel. J Clin Psychiatry. 1997;58(suppl 7):5-10.
33. Balon R. SSRI-associated sexual dysfunction. Am J Psychiatry. 2006;163(9):1504-1509, quiz 1664.
34. Mahableshwarkar AR, Jacobsen PL, Serenko M, et al. A randomized, doubleblind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. Poster presented at the 166th American Psychiatric Association (APA) Annual Meeting; May 18-22, 2013; San Francisco, CA.